InvestorsHub Logo
icon url

couldbebetter

09/21/20 3:28 PM

#300403 RE: circuitcity #300399

What I find hard to fathom is that if he found a reasonable buyer for AMRN
he and the entire management team would benefit the most. If they know
that selling AMRN is the best way to create shareholder value, not to
mention making Vascepa more widely available through an established
distribution network, what would keep them from pursuing such a deal?
Basically, it is common sense and logical that Vascepa would be a much
more successful drug if BP owned it. Let's hope the big institutions
will see it that way as well. Until then, I will perter IR with my
very polite rants to sell the company or replace JT with someone
who can.
icon url

raistthemage

09/21/20 3:37 PM

#300406 RE: circuitcity #300399

Breach of fiduciary is should I dare say "obvious". The reason why is that they've kept Kennedy on so far...

You just can't survive as chief counsel after this kind of disaster unless the leadership is just looking out for themselves.

En Banc would have a much better chance if we had a dissenter on the initial panel but unfortunately we had none.